Toxic clozapine level as first indication of severe, acute infection.

The Mental Health Clinician Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI:10.9740/mhc.2022.01.045
Erica A K Davis, Tyler Hightower, Katherine Ann Cinnamon
{"title":"Toxic clozapine level as first indication of severe, acute infection.","authors":"Erica A K Davis,&nbsp;Tyler Hightower,&nbsp;Katherine Ann Cinnamon","doi":"10.9740/mhc.2022.01.045","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clozapine levels can be influenced by many factors, including pharmacogenomic variability, pharmacokinetic drug interactions, and infection/inflammation. The concentration-to-dose ratio (C/D), a measure of a medication's rate of metabolism and clearance, may increase during an acute infection due to decreased medication metabolism and clearance.</p><p><strong>Case report: </strong>A 56-year-old White man was restarted on clozapine and titrated up to 350 mg/d with therapeutic steady-state levels (C/D 1.11) on hospital day (HD) 69. At this time, he was also being treated for COPD exacerbation. For the next month, he continued to complain of cough, but vital signs and chest x-ray remained normal. Labs were unremarkable except for occasional leukocytosis that would resolve on repeat evaluation. A routine clozapine level drawn on HD 104, resulted on day 108 and showed clozapine toxicity with C/D 4.05, although the patient was asymptomatic. After receipt of labs on day 109, showing elevated WBC count, he was immediately sent to the emergency room where he was admitted for treatment of pneumonia. On return to the state hospital, the patient was continued on 100 mg clozapine and titrated to 200 mg/d based on low drug levels. He continued to do well on 200 mg/d clozapine with C/D averaging 1.13 (range, 0.75-1.52).</p><p><strong>Discussion: </strong>Acute infection and illness can lead to significantly increased clozapine levels and toxicity, even if symptoms of toxicity are minimal or absent. This appears to be the first report of a toxic level being the first indication of severe medical illness.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"45-48"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/38/i2168-9709-12-1-45.PMC8788300.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2022.01.045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clozapine levels can be influenced by many factors, including pharmacogenomic variability, pharmacokinetic drug interactions, and infection/inflammation. The concentration-to-dose ratio (C/D), a measure of a medication's rate of metabolism and clearance, may increase during an acute infection due to decreased medication metabolism and clearance.

Case report: A 56-year-old White man was restarted on clozapine and titrated up to 350 mg/d with therapeutic steady-state levels (C/D 1.11) on hospital day (HD) 69. At this time, he was also being treated for COPD exacerbation. For the next month, he continued to complain of cough, but vital signs and chest x-ray remained normal. Labs were unremarkable except for occasional leukocytosis that would resolve on repeat evaluation. A routine clozapine level drawn on HD 104, resulted on day 108 and showed clozapine toxicity with C/D 4.05, although the patient was asymptomatic. After receipt of labs on day 109, showing elevated WBC count, he was immediately sent to the emergency room where he was admitted for treatment of pneumonia. On return to the state hospital, the patient was continued on 100 mg clozapine and titrated to 200 mg/d based on low drug levels. He continued to do well on 200 mg/d clozapine with C/D averaging 1.13 (range, 0.75-1.52).

Discussion: Acute infection and illness can lead to significantly increased clozapine levels and toxicity, even if symptoms of toxicity are minimal or absent. This appears to be the first report of a toxic level being the first indication of severe medical illness.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
毒性氯氮平水平是严重急性感染的第一指征。
背景:氯氮平水平受多种因素影响,包括药物基因组变异性、药代动力学药物相互作用和感染/炎症。浓度剂量比(C/D)是衡量药物代谢和清除率的指标,在急性感染期间可能由于药物代谢和清除率降低而增加。病例报告:一名56岁白人男性在住院日(HD) 69重新开始使用氯氮平,并滴定至350mg /d,达到治疗稳态水平(C/ d 1.11)。此时,他也在接受慢性阻塞性肺病加重治疗。在接下来的一个月里,他一直抱怨咳嗽,但生命体征和胸部x光片都很正常。除偶尔出现白细胞增多外,实验室无明显异常,可在重复检查时消除。第108天HD 104的氯氮平常规水平显示氯氮平毒性,C/D为4.05,尽管患者无症状。在第109天收到化验单后,显示白细胞计数升高,他立即被送往急诊室接受肺炎治疗。返回州立医院后,患者继续服用100毫克氯氮平,并根据低药物水平滴定至200毫克/天。他继续服用200mg /d氯氮平,C/ d平均为1.13(范围为0.75-1.52)。讨论:急性感染和疾病可导致氯氮平水平和毒性显著增加,即使毒性症状很轻微或没有。这似乎是毒性水平作为严重医学疾病的第一个指征的第一个报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital Barriers to access to psychiatric medications in Missouri county jails Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1